ASX:PBPProbiotec Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Probiotec Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$1.88 -0.04 (-2.08 %) (As of 05/13/2020) Add Compare Share Today's RangeA$1.88Now: A$1.88▼A$1.9250-Day RangeA$1.88MA: A$1.88▼A$1.8852-Week RangeA$1.50Now: A$1.88▼A$2.48Volume26,253 shsAverage VolumeN/AMarket Capitalization$140.58 millionP/E RatioN/ADividend Yield2.01%BetaN/A ProfileAdvanced ChartCompetitorsDividendEarningsInsider TradesHeadlines Probiotec Limited develops, manufactures, and sells pharmaceutical, consumer health, and nutraceutical products in Australia and internationally. The company operates in three segments: Branded Pharmaceuticals, Contract Manufacture, and Obesity and Weight Management. It primarily engages in the contract manufacturing of pharmaceutical, food, and animal nutrition products for pharmaceutical and food companies; manufacture and sale of a range of obesity and weight management products in various channels, including FMCG, pharmacy, health food stores, and online; and provision of Celebrity Slim and Impromy weight loss programs. The company also provides owned and licensed branded pharmaceutical products, over-the-counter pharmaceutical products, complementary medicines, and specialty ingredients. Probiotec Limited was founded in 1997 and is based in Laverton North, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Probiotec. Previous Next 2.6 Community Rank Outperform VotesProbiotec has received 18 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProbiotec has received 17 “underperform” votes. (Add your “underperform” vote.)Community SentimentProbiotec has received 51.43% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Probiotec and other stocks. Vote “Outperform” if you believe PBP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PBP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.8 Dividend Strength Dividend YieldProbiotec pays a meaningful dividend of 2.01%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthProbiotec does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Probiotec insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$121,203.00 in company stock and sold A$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Probiotec is -134.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Probiotec is -134.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProbiotec has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.8Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolASX:PBP Previous Symbol CUSIPN/A CIKN/A Webwww.probiotec.com.au Phone61 3 9278 7555Debt Debt-to-Equity Ratio67.32 Current Ratio1.76 Quick Ratio1.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$90.17 million Price / Sales1.56 Cash FlowA$0.11 per share Price / Cash Flow16.79 Book ValueA$0.79 per share Price / Book2.39Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares74,778,896Market Cap$140.58 million Next Earnings DateN/A OptionableNot Optionable Receive PBP News and Ratings via Email Sign-up to receive the latest news and ratings for PBP and its competitors with MarketBeat's FREE daily newsletter. Probiotec (ASX:PBP) Frequently Asked Questions How has Probiotec's stock been impacted by COVID-19 (Coronavirus)? Probiotec's stock was trading at A$1.98 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PBP stock has decreased by 5.1% and is now trading at A$1.88. View which stocks have been most impacted by Coronavirus. How were Probiotec's earnings last quarter? Probiotec Limited (ASX:PBP) announced its earnings results on Tuesday, February, 26th. The company reported $0.02 earnings per share (EPS) for the quarter. View Probiotec's earnings history. How often does Probiotec pay dividends? What is the dividend yield for Probiotec? Probiotec announced a Interim dividend on Tuesday, February 25th. Stockholders of record on Thursday, March 19th will be paid a dividend of 0.015 per share on Thursday, March 19th. This represents a dividend yield of 0.71%. The ex-dividend date of this dividend is Tuesday, March 3rd. This is a boost from Probiotec's previous Interim dividend of A$0.01. View Probiotec's dividend history. Has Probiotec been receiving favorable news coverage? Media coverage about PBP stock has trended positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Probiotec earned a news impact score of 2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Probiotec. Who are some of Probiotec's key competitors? Some companies that are related to Probiotec include Hexo (HEXO), OrganiGram (OGI), HEXO (HEXO), Next Science (NXS), Amryt Pharma (AMYT), ICC Labs (ICC), Benchmark (BMK), Green Organic Dutchman (TGOD), ESSA Pharma (EPI), cbdMD (YCBD), Shield Therapeutics (STX), Althea Group (AGH), WeedMD (WMD), Delta 9 Cannabis (NINE) and Supreme Cannabis (FIRE). View all competitors. What other stocks do shareholders of Probiotec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Probiotec investors own include Kalium Lakes (KLL) and 5G Networks (5GN). Who are Probiotec's key executives? Probiotec's management team includes the following people: Mr. Wesley Stringer B.Comm, LLB (Hons), CPA, CEO, MD & Exec. DirectorMr. Jared Stringer, CFO, Company Sec. & Financial ControllerMs. Julie McIntosh, Chief Operating OfficerMr. Alan Hong, Gen. Mang. of AccountingMr. Dustin Stringer, Gen. Mang. of Marketing What is Probiotec's stock symbol? Probiotec trades on the ASX under the ticker symbol "PBP." What is Probiotec's stock price today? One share of PBP stock can currently be purchased for approximately A$1.88. How big of a company is Probiotec? Probiotec has a market capitalization of $140.58 million and generates $90.17 million in revenue each year. What is Probiotec's official website? The official website for Probiotec is www.probiotec.com.au. How can I contact Probiotec? The company can be reached via phone at 61 3 9278 7555. This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
